Efficacy & Safety of Octaplas for Liver Disease and Liver Transplantation
Effects of octaplas and FFP in the management of coagulopathy in liver disease and liver transplantation1,2
- Prospective, single-blind, randomized study was designed to investigate the safety and efficacy of octaplas compared with standard FFP in adult patients with coagulopathies due to liver disease or liver transplantation
- Study was not powered to detect a difference in efficacy
|STUDY OBJECTIVES: ASSESS EFFICACY AND TOLERABILITY OF OCTAPLAS
IN CORRECTING THE COAGULOPATHY ASSOCIATED WITH LT AND LD
|N (Male/Female)||LT: 12 (5/7)
LD: 13 (10/3)
|LT: 13 (7/6)
LD: 11 (8/3)
|Median age (range)||LT: 47 years (20-66)
LD: 50 years (30-69)
|LT: 51 years (23-67)
LD: 52 years (26-66)
|Median dosage (range)||LT: 44 mL/kg (25-104)
LD: 12 mL/kg (11-15)
|LT: 44 mL/kg (7-98)
LD: 13 mL/kg (11-17) Conclusions
LT = Liver Transplant, LD = Liver Disease.
- Similar correction of increased international normalized ratio (INR) and prolonged aPTT values achieved by 24 hours post-treatment
- Similar number of blood components transfused with both octaplas and FFP
- No viral transmission or infections reported. No febrile reactions observed. One patient had a mild reaction to octaplas (nausea and pruritus)
- Williamson LM, Llewelyn NC, Fisher JP, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999; 39:1227-1234.
- Freeman, JW, Williamson LM, Llewelyn C, et al. A randomized trial of solvent/detergent and standard fresh-frozen plasma in the treatment of the coagulopathy seen during orthotopic liver transplantation. Vox Sang 1998; 74(suppl 1):225- 229.